Investor directory

Sana Biotechnology

Sana Biotechnology is a biotechnology company focused on creating engineered cells as medicines to treat a variety of diseases. Established in 2018 and headquartered in Seattle, Washington, with additional offices in South San Francisco and Cambridge, the company develops innovative therapies through cell engineering to address unmet medical needs in areas such as oncology, diabetes, autoimmune disorders, and central nervous system conditions. By reprogramming or replacing damaged cells and tissues, Sana aims to pioneer new treatment approaches and deliver meaningful healthcare solutions. Its product pipeline includes several candidates designed to tackle these diverse therapeutic challenges.

Top Stages

Acquisition
http://sana.com
https://crunchbase.com/organization/sana-biotechnology
https://linkedin.com/company/sana-biotechnology
https://pitchbook.com/profiles/company/264461-32
https://www.capitaliq.com/CIQDotNet/company.aspx?companyId=597313585

Richard Mulligan Ph.D

Vice Chairman

1 past transactions

Oscine Therapeutics

Acquisition in 2020
Oscine Therapeutics is a biotechnology company that originated from research at the University of Rochester Medical Center. The company focuses on developing a cell therapy platform that leverages stem cell science to transform the treatment of central nervous system (CNS) diseases. Oscine's platform generates bipotential astrocyte-oligodendrocyte glial progenitor cells, which can replace lost, damaged, or dysfunctional glial cells in patients suffering from degenerative diseases and conditions affecting white matter. By facilitating the restoration of these critical cells, Oscine Therapeutics aims to enhance research efforts and expand treatment possibilities for combating degeneration and potentially curing various CNS disorders.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.